Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
Status:
Completed
Trial end date:
2018-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess Abatacept Intravenous (IV) effectiveness in patients
with inadequate response to one or more conventional Disease Modifying Against Rheumatism
(DMARDs) including Methotrexate in France, through the estimation of Abatacept retention rate
over 2 years and reasons of discontinuation